Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J8522
50 MG
Medicare payment limit per unit (Q4 2026): $0.029
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| DME supplier services | 150 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$0.029per 50 MG
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.029 | 50 MG | 20% | −63.8% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.080 | 50 MG | 20% | +166.7% | — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.030 | 50 MG | 20% | −21.1% | — |
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $0.038 | 50 MG | 20% |
Medicare hospital outpatient (OPPS) · Q4 2026
K Paid separately (non-pass-through drug or biological)
$0.029 per unit · APC 0804 · copayment $0.010 per unit
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 16729-0072-12 | CapecitabineAccord Healthcare Inc | 60 × 1 | 180 | 180 | $5.22 | ASP | Q4 2024 – Q4 2026 | ListedCapecitabine |
| 16729-0073-29 | CapecitabineAccord Healthcare Inc | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q4 2024 – Q4 2026 | ListedCapecitabine |
| 60687-0149-94 | CapecitabineAmerican Health Packaging | 20 × 1 | 200 | 200 | $5.80 | ASP | Q4 2024 – Q4 2026 | ListedCapecitabine |
| 67877-0458-60 | CapecitabineAscend Laboratories, LLC | 60 × 1 | 180 | 180 | $5.22 | ASP | Q4 2025 – Q4 2026 | ListedCapecitabine |
| 67877-0459-12 | CapecitabineAscend Laboratories, LLC | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q4 2025 – Q4 2026 | ListedCapecitabine |
| 59651-0204-60 | CapecitabineAurobindo Pharma Usa, Inc. | 60 × 1 | 180 | 180 | $5.22 | ASP | Q1 2026 – Q4 2026 | ListedCapecitabine |
| 59651-0205-08 | CapecitabineAurobindo Pharma Usa, Inc. | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q1 2026 – Q4 2026 | ListedCapecitabine |
| 68001-0487-06 | CapecitabineBluePoint Laboratories | 60 × 1 | 180 | 180 | $5.22 | ASP | Q4 2024 – Q4 2026 | Excluded listingCapecitabine |
| 68001-0488-07 | CapecitabineBluePoint Laboratories | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q4 2024 – Q4 2026 | Excluded listingCapecitabine |
| 68001-0643-06 | CapecitabineBluePoint Laboratories | 60 × 1 | 180 | 180 | $5.22 | ASP | Q4 2025 – Q4 2026 | ListedCapecitabine |
| 68001-0644-07 | CapecitabineBluePoint Laboratories | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q4 2025 – Q4 2026 | ListedCapecitabine |
| 69097-0948-08 | CapecitabineCipla USA, Inc. | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q4 2024 – Q4 2026 | ListedCapecitabine |
| 69097-0949-03 | CapecitabineCipla USA, Inc. | 60 × 1 | 180 | 180 | $5.22 | ASP | Q4 2024 – Q4 2026 | ListedCapecitabine |
| 55111-0496-60 | CapecitabineDr. Reddy's Laboratories Inc. | 60 × 1 | 180 | 180 | $5.22 | ASP | Q1 2026 – Q4 2026 | ListedCapecitabine |
| 55111-0497-04 | CapecitabineDr. Reddy's Laboratories Inc. | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q1 2026 – Q4 2026 | ListedCapecitabine |
| 00004-1100-20 | XelodaGenentech, Inc. | 60 × 1 | 180 | 180 | $5.22 | ASP | Q4 2024 – Q4 2026 | Excluded listingXeloda |
| 00004-1101-50 | CapecitabineGenentech, Inc. | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q4 2024 – Q4 2026 | Excluded listingXeloda |
| 61269-0470-60 | XelodaH2 Pharma LLC | 60 × 1 | 180 | 180 | $5.22 | ASP | Q1 2026 – Q4 2026 | Excluded listingXeloda |
| 70756-0815-60 | CapecitabineLifestar Pharma | 60 × 1 | 180 | 180 | $5.22 | ASP | Q4 2024 – Q4 2026 | ListedCapecitabine |
| 70756-0816-22 | CapecitabineLifestar Pharma | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q4 2024 – Q4 2026 | ListedCapecitabine |
| 72205-0006-60 | CapecitabineNovadoz Pharmaceuticals LLC | 60 × 1 | 180 | 180 | $5.22 | ASP | Q1 2026 – Q4 2026 | ListedCapecitabine |
| 72205-0007-92 | CapecitabineNovadoz Pharmaceuticals LLC | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q1 2026 – Q4 2026 | ListedCapecitabine |
| 82009-0112-12 | CapecitabineQuallent Pharmaceuticals | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q1 2026 – Q4 2026 | ListedCapecitabine |
| 00093-7473-06 | CapecitabineTeva Pharmaceuticals USA, Inc. | 60 × 1 | 180 | 180 | $5.22 | ASP | Q4 2024 – Q4 2026 | ListedCapecitabine |
| 00093-7474-89 | CapecitabineTeva Pharmaceuticals USA, Inc. | 120 × 1 | 1,200 | 1,200 | $34.80 | ASP | Q4 2024 – Q4 2026 | ListedCapecitabine |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 65162-0843-06 | CapecitabineAMNEAL PHARMACEUTICALS, LLC | 60 × 1 | 180 | 180 | ASP | Q4 2024Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q2 2025 | Dates changed | N — No maintenance | Added Oct 1, 2024 · action effective Jan 1, 2025 · termination — |
| Q4 2024 | Added to HCPCS | A — Added | Added date Oct 1, 2024 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| +2.7% |
| — |
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $0.037 | 50 MG | 20% | −30.2% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $0.053 | 50 MG | 20% | −18.5% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $0.065 | 50 MG | 20% | +62.5% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $0.040 | 50 MG | 20% | −37.5% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $0.064 | 50 MG | 20% | — | Added October 2024 |
|---|
| 65162-0844-16 | CapecitabineAMNEAL PHARMACEUTICALS, LLC | 120 × 1 | 1,200 | 1,200 | ASP | Q4 2024 – Q1 2025Not in Q4 2026 file | Excluded listingCapecitabine |
|---|
| 72485-0204-60 | CapecitabineARMAS PHARMACEUTICALS, INC. | 60 × 1 | 180 | 180 | ASP | Q4 2024Not in Q4 2026 file | ListedCapecitabine 150mg |
|---|
| 72485-0205-12 | CapecitabineARMAS PHARMACEUTICALS, INC. | 120 × 1 | 1,200 | 1,200 | ASP | Q4 2024Not in Q4 2026 file | ListedCapecitabine 500mg |
|---|
| 00054-0271-21 | CapecitabineHikma Pharmaceuticals USA Inc. | 60 × 1 | 180 | 180 | ASP | Q4 2024Not in Q4 2026 file | Excluded listingCapecitabine |
|---|
| 00054-0272-23 | CapecitabineHikma Pharmaceuticals USA Inc. | 120 × 1 | 1,200 | 1,200 | ASP | Q4 2024Not in Q4 2026 file | Excluded listingCapecitabine |
|---|
| 00378-2511-91 | CapecitabineMYLAN PHARMACEUTICALS, INC | 60 × 1 | 180 | 180 | ASP | Q4 2024Not in Q4 2026 file | Excluded listingCapecitabine |
|---|
| 00378-2512-78 | CapecitabineMYLAN PHARMACEUTICALS, INC | 120 × 1 | 1,200 | 1,200 | ASP | Q4 2024Not in Q4 2026 file | Excluded listingCapecitabine |
|---|
| 16714-0467-01 | CapecitabineNorthstar RxLLC | 60 × 1 | 180 | 180 | ASP | Q4 2024 – Q3 2026Not in Q4 2026 file | Excluded listingCapecitabine |
|---|
| 16714-0468-01 | CapecitabineNorthstar RxLLC | 120 × 1 | 1,200 | 1,200 | ASP | Q4 2024 – Q3 2026Not in Q4 2026 file | Excluded listingCapecitabine |
|---|